Keywords: alza, enrolling, ks, patients, im862, trial, corp

Alza enrolling KS patients in IM862 trial

Article | 27 July 2000

Print This

Alza Corp is enrolling AIDS-related Kaposi's sarcoma patients in aPhase III trial to evaluate IM862, an angiogenesis inhibitor developed by ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in